Benzinga – Needham analyst David Saxon reiterated a Buy rating on SI-BONE, Inc (NASDAQ: SIBN), raising the price target to $32 from $27. The analyst expects SIBN to beat and raise in 2Q and believes there is further upside to 2H23 estimates. The analyst notes that sales force expansion, surgeon…Read More
SIBONE Poised For A Surge Analyst Highlights Upside Potential With New Product Launches By Benzinga
